UT AND QUATTROMED PLC APPLY FOR A U.S. PATENT
The filing will be followed by 10 months of studies in the
laboratories of Quattromed plc, a spin-off from UT, to assess the
industrial applicability of the work of UT scientists. The authors of
the methodology are Toomas Silla, Ingrid Hääl, Yelizaveta Geimanen,
Kadri Janikson, Aare Abroi, Ene Ustav, Mart Ustav and Tiiu Mandel, all
of the UT Institute of Molecular and Cell Biology.
”Where
so far in international practice the setting up of production lines for
proteins used to take 10-12 months, switching to the novel type of
protein lines allows us to cut our production process down to 2-3
months. Such an economy of time represents an important development for
our customers in launching drug development programmes,” explained Erki
Mölder, Executive Director of Quattromed plc.
”Our
collaboration with Quattromed plc has been an active one since the
company started, and will hopefully continue as intensively also in the
future,” says Jane Saatre, Head of the Technology Licensing Department
of UT Institute of Technology, throwing light on the background of the
joint activities.
For the last five years, the developed
methodology constitutes an eighth scientific result of potential
commercial value to protect which UT has filed for a patent. During
that period, over 50 patent applications have been filed in Europe, the
US and Japan in protection of UT inventions. UT patents portfolio is
managed by the UT Institute of Technology.
Quattromed plc is
Estonia’s leading firm in the field of molecular diagnostics. The
company’s IP portfolio contains three patent applications, a dozen
technology licences and one trade mark.
Illari Lään
Head, UT Public Relations and Information Office
Additional information: UT Institute of Technology, Ms Jane Saatre,
tel. +372-737-4804, +372-52-97956; Quattromed plc, Mr Erki Mölder, tel.
+372-737-7070